Nyrada On Track To Being Site Initiation Visits For Phase IIa Clinical Trial
MT Newswires Live
Mar 19
Nyrada (ASX:NYR) said it was on track to begin site initiation visits for its PROTECT-MI Phase IIa trial, which is designed to assess the safety and preliminary efficacy of its drug candidate Xolatryp in addressing myocardial ischemia reperfusion injury in patients suffering a STEMI heart attack, in
March, according to a Thursday Australian bourse filing.
Seven hospitals were selected as initial sites, with the first patient dosing expected in April. The enrolment of patients in the PROTECT-MI study will finish once 100 evaluable patients are dosed.
Its shares fell 2% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.